QDEL (QuidelOrtho) Tax Provision : $80 Mil (TTM As of Dec. 2024)

View and export this data going back to 1992. Start your Free Trial

What is QuidelOrtho Tax Provision?

QuidelOrtho's tax provision for the three months ended in Dec. 2024 was $-38 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $80 Mil.

QuidelOrtho Tax Provision Historical Data

The historical data trend for QuidelOrtho's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Tax Provision Chart

QuidelOrtho Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

-230.03

-196.10

-187.20

19.00

79.50

QuidelOrtho Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															16.20	92.90	15.20	8.90	-37.50

QuidelOrtho Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $80 Mil.

QuidelOrtho Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

0A55:UK QL1A:Germany

Address

9975 Summers Ridge Road, San Diego, CA, USA, 92121

Website

https://www.quidelortho.com

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.

Executives

Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Joseph M Busky	officer: Chief Financial Officer	1717 DEERFIELD ROAD, DEERFIELD IL 60015
Louise Brandy	officer: SVP, Chief Information Officer	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein	officer: Chief Administrative Officer	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Tc Group Vi Cayman, L.l.c.	10 percent owner	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Christopher M Smith	director	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Douglas C Bryant	director, officer: Chairman & CEO	C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Michelle A. Hodges	officer: SVP, General Counsel	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Wilkins Joseph D Jr.	director	82414 PUCCINI DRIVE, INDIO CA 92203
Robert Joseph Bujarski	officer: See Remarks	C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen H. Wise	director	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli	officer: SVP, Molecular Bus. Unit	9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Robert R. Schmidt	director	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Kenneth F Buechler	director
Werner Kroll	officer: SVP, Research and Development	12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130